4-DL-alanyl-morpholine; hydrochloride | 24152-98-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-DL-alanyl-morpholine; hydrochloride
• 英文别名: 4-DL-Alanyl-morpholin; Hydrochlorid；2-Amino-1-(morpholin-4-yl)propan-1-one hydrochloride；2-amino-1-morpholin-4-ylpropan-1-one;hydrochloride
• CAS: 24152-98-5
• 化学式: C₇H₁₄N₂O₂*ClH
• mdl: MFCD13561994
• 分子量: 194.661
• InChiKey: YNWMLIPTMXEEGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.16
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  55.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 氯仿 作用下， 生成 4-DL-alanyl-morpholine; hydrochloride
  参考文献：
  名称：

  124.唑系列的研究。第二十六部分 碱对2-硫代-4-甲基-5-噻唑烷酮的作用

  摘要：

  DOI：

  10.1039/jr9500000642

文献信息

• COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20130190289A1

  公开（公告）日：2013-07-25

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物由结构式(I)或其药学上可接受的盐所代表，其中结构式(I)的变量如规范和权利要求所描述。一种药物组合物包括一种由结构式(I)或其药学上可接受的盐所代表的化合物，以及药学上可接受的载体或赋形剂。一种治疗HCV感染的方法包括向受试者施用一种由结构式(I)或其药学上可接受的盐所代表的治疗有效量的化合物。一种抑制或减少受试者或生物体外样本中HCV聚合酶活性的方法包括向受试者或样本中施用一种由结构式(I)或其药学上可接受的盐所代表的治疗有效量的化合物。
• US6476235B2
  申请人：——

  公开号：US6476235B2

  公开（公告）日：2002-11-05
• US6545153B1
  申请人：——

  公开号：US6545153B1

  公开（公告）日：2003-04-08
• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT OU LA PRÉVENTION D'INFECTIONS PAR FLAVIVIRUS
  申请人：VERTEX PHARMA

  公开号：WO2012006055A2

  公开（公告）日：2012-01-12

  A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
• 124. Studies in the azole series. Part XXVI. The action of bases on 2-thio-4-methyl-5-thiazolidone
  作者：A. H. Cook、A. L. Levy

  DOI：10.1039/jr9500000642

  日期：——